Liraglutide : new results in the treatment of type 2 diabetes mellitus
Copyright 2012 Prous Science, S.A.U. or its licensors. All rights reserved..
New drugs for type 2 diabetes that act on incretin metabolism have been shown to improve glycemic control, reduce body weight and have a low risk for hypoglycemia. Among these, liraglutide is the first glucagon-like peptide 1 (GLP-1) analogue approved for subcutaneous, once-daily administration. According to results from clinical trials, liraglutide is an attractive alternative for the early treatment of type 2 diabetes. The results of the LEAD (Liraglutide Effect and Action in Diabetes) study program demonstrated the efficacy and safety of liraglutide in terms of reduction of glycated hemoglobin (HbA1c) levels, significant loss of body weight that was maintained over the long term, better control of the lipid profile and systolic arterial pressure, reduction of the risk for hypoglycemia and reduction of cardiovascular risk. Moreover, the drug was demonstrated to be safe and can be co-administered with oral antidiabetic agents. The product's tolerability has been demonstrated, with nausea as the most common adverse event, which waned from the fourth week of treatment.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2012 |
|---|---|
| Erschienen: |
2012 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:48 Suppl B |
|---|---|
| Enthalten in: |
Drugs of today (Barcelona, Spain : 1998) - 48 Suppl B(2012) vom: 01. Juli, Seite 1-17 |
| Sprache: |
Portugiesisch |
|---|
| Weiterer Titel: |
Liraglutida: novos resultados no tratamento do diabetes mellitus tipo 2 |
|---|
| Beteiligte Personen: |
Mateos, J L [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 28.11.2012 Date Revised 07.12.2022 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1358/dot.2012.48(Suppl.B).1876681 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM221957057 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM221957057 | ||
| 003 | DE-627 | ||
| 005 | 20231224053127.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231224s2012 xx |||||o 00| ||por c | ||
| 024 | 7 | |a 10.1358/dot.2012.48(Suppl.B).1876681 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0740.xml |
| 035 | |a (DE-627)NLM221957057 | ||
| 035 | |a (NLM)23082308 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a por | ||
| 100 | 1 | |a Mateos, J L |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Liraglutide |b new results in the treatment of type 2 diabetes mellitus |
| 246 | 3 | 3 | |a Liraglutida: novos resultados no tratamento do diabetes mellitus tipo 2 |
| 264 | 1 | |c 2012 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 28.11.2012 | ||
| 500 | |a Date Revised 07.12.2022 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright 2012 Prous Science, S.A.U. or its licensors. All rights reserved. | ||
| 520 | |a New drugs for type 2 diabetes that act on incretin metabolism have been shown to improve glycemic control, reduce body weight and have a low risk for hypoglycemia. Among these, liraglutide is the first glucagon-like peptide 1 (GLP-1) analogue approved for subcutaneous, once-daily administration. According to results from clinical trials, liraglutide is an attractive alternative for the early treatment of type 2 diabetes. The results of the LEAD (Liraglutide Effect and Action in Diabetes) study program demonstrated the efficacy and safety of liraglutide in terms of reduction of glycated hemoglobin (HbA1c) levels, significant loss of body weight that was maintained over the long term, better control of the lipid profile and systolic arterial pressure, reduction of the risk for hypoglycemia and reduction of cardiovascular risk. Moreover, the drug was demonstrated to be safe and can be co-administered with oral antidiabetic agents. The product's tolerability has been demonstrated, with nausea as the most common adverse event, which waned from the fourth week of treatment | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 7 | |a Blood Glucose |2 NLM | |
| 650 | 7 | |a Glycated Hemoglobin A |2 NLM | |
| 650 | 7 | |a Hypoglycemic Agents |2 NLM | |
| 650 | 7 | |a Incretins |2 NLM | |
| 650 | 7 | |a Pyrazines |2 NLM | |
| 650 | 7 | |a Sulfonylurea Compounds |2 NLM | |
| 650 | 7 | |a Triazoles |2 NLM | |
| 650 | 7 | |a glimepiride |2 NLM | |
| 650 | 7 | |a 6KY687524K |2 NLM | |
| 650 | 7 | |a Liraglutide |2 NLM | |
| 650 | 7 | |a 839I73S42A |2 NLM | |
| 650 | 7 | |a Glucagon-Like Peptide 1 |2 NLM | |
| 650 | 7 | |a 89750-14-1 |2 NLM | |
| 650 | 7 | |a Sitagliptin Phosphate |2 NLM | |
| 650 | 7 | |a TS63EW8X6F |2 NLM | |
| 700 | 1 | |a Wajchenberg, B L |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Drugs of today (Barcelona, Spain : 1998) |d 1998 |g 48 Suppl B(2012) vom: 01. Juli, Seite 1-17 |w (DE-627)NLM123139600 |x 1699-3993 |7 nnns |
| 773 | 1 | 8 | |g volume:48 Suppl B |g year:2012 |g day:01 |g month:07 |g pages:1-17 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1358/dot.2012.48(Suppl.B).1876681 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 48 Suppl B |j 2012 |b 01 |c 07 |h 1-17 | ||